1. Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer
   Gustavo A. Arias-Pinilla et al, 2018, Oncotarget CrossRef
2. The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance
   Kalyani Patil et al, 2021, Cancer and Metastasis Reviews CrossRef
3. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker
   Jérémy Nigri et al, 2017, Cellular and Molecular Life Sciences CrossRef
4. Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines
   Emma Grant et al, 2022, PLOS ONE CrossRef
5. Niraparib-induced STAT3 inhibition increases its antitumor effects
   Qianqian Zhao et al, 2022, Frontiers in Oncology CrossRef
6. Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
   Sunanda Singh et al, 2023, International Journal of Molecular Sciences CrossRef
7. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
   Emilia Rabia et al, 2021, mAbs CrossRef
8. Integration of Antibody Array Technology into Drug Discovery and Development
   Wei Huang et al, 2018, ASSAY and Drug Development Technologies CrossRef
9. Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies
   L. V. K. S. Bhaskar et al, 2018, Role of Tyrosine Kinases in Gastrointestinal Malignancies CrossRef
10. Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma
    James T. Topham et al, 2023, Therapeutic Advances in Medical Oncology CrossRef
11. Unraveling the Molecular Tumor-Promoting Regulation of Cofilin-1 in Pancreatic Cancer
    Silke D. Werle et al, 2021, Cancers CrossRef
12. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
    Ahmad A. Zulkifli et al, 2017, Molecular and Cellular Endocrinology CrossRef
13. A targetable pathway to eliminate TRA-1-60+/TRA-1-81+ chemoresistant cancer cells
    Lei Tan et al, 2023, Journal of Molecular Cell Biology CrossRef
14. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition
    Timothy J. Stuhlmiller et al, 2017, Journal of the American Heart Association CrossRef
15. HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer
    Sarrah L. Hasanali et al, 2021, Clinical Cancer Research CrossRef
16. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
    Motahareh Mortazavi et al, 2022, Critical Reviews in Oncology/Hematology CrossRef
17. EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis
    Szu-Wei Lee et al, 2019, Developmental Cell CrossRef
18. Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer
    Gustavo A. Arias-Pinilla et al, 2020, Scientific Reports CrossRef
19. Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
    Chiara Varamo et al, 2019, Cancers CrossRef
20. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications
    Arkadiusz Gzil et al, 2019, Molecular Biology Reports CrossRef
21. Development of Erasin: a chromone-based STAT3 inhibitor which induces apoptosis in Erlotinib-resistant lung cancer cells
    Christian Lis et al, 2017, Scientific Reports CrossRef